ClinicalTrials.gg
RecruitingNCT07511361KARDINAL-ASHUpdated Oct 15, 2026

Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension

A Phase 2 interventional study of Tonlamarsen and Placebo in Hypertension, Acute Severe Hypertension and Hypertensive Emergency, sponsored by Kardigan, Inc.. Recruiting at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Primary conditionHypertensive CrisisRegistry: HypertensionReclassifiedWhy we changed it
Registry
Hypertension — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypertensive Crisis
Why
  1. The study's listed conditions name Hypertensive Crisis, a narrower term within Hypertension.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Kardigan, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 15, 2026Site recruiting status changed2 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Hypertensive Crisis with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Hypertensive Crisis · United States.

Started
2026
the only one that year
Phase 2
Only one
of the 13
Registered
13th of 13
by date
Lead sponsor
1 of 13
Kardigan, Inc.

Among the 13 studies in Hypertensive Crisis with a site in United States, this one is the only one that started in 2026, is the only one in phase 2, and was the 13th registered.

Hypertensive Crisis

31 studies on the registry are indexed under Hypertensive Crisis; 9 are open to participants now.

Browse Hypertensive Crisis studies →

Open to participants now

2 of the 13 studies in Hypertensive Crisis with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Hypertensive Crisis studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Hypertensive Crisis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the blood pressure-lowering effect of tonlamarsen in adult participants who were recently hospitalized and concurrently experienced an episode of acute severe hypertension.

Read the detailed description

The Sponsor is studying an investigational medication called tonlamarsen to determine if it can help people recently treated for acute severe hypertension (hypertensive emergency and urgency).

The purpose of this study is to evaluate how well tonlamarsen works compared to a placebo and to see how safe it is for people following a recent episode of acute severe hypertension. Tonlamarsen is designed to block the body's liver from making a protein called angiotensinogen (AGT), which plays a key role in controlling blood pressure.

The main goals of the study are:

  • To assess the effect of tonlamarsen on the amount of AGT in blood over time
  • To assess the effect of tonlamarsen on blood pressure
  • To evaluate the safety and tolerability of tonlamarsen

Participants will:

  • Receive monthly doses of tonlamarsen for approximately 3 months
  • Visit the clinic about 7 times, including initial evaluation, checkups, tests, and follow-up
03

Conditions studied

  • Hypertension
  • Acute Severe Hypertension
  • Hypertensive Emergency
  • Hypertensive Urgency

Browse trials for

04

In context

Hypertensive Crisis Reclassified

31 studies on the registry are indexed under Hypertensive Crisis; 9 are open to participants now.

This study's planned enrollment of 140 is close to the median of 140 across 19 interventional studies indexed under Hypertensive Crisis.

Browse Hypertensive Crisis studies →

Lead sponsor

Kardigan, Inc. is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Compared within Hypertensive Crisis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Age 18 or older, body weight ≥ 50 kg with ≤45.0 kg/m2
  • Ready for discharge or recently discharged from the hospital to home (within the past 7 days) during which evaluation and/or treatment of acute severe hypertension (documented SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg) occurred, as measured by a healthcare provider (HCP) within the 24 hours preceding hospitalization or during the initial 24 hours of hospitalization
  • At Screening and Randomization visit, average resting office systolic blood pressure ≥ 145 mmHg
  • Presence of established cardiovascular or renal disease

Key Exclusion Criteria:

  • Has known history of secondary hypertension
  • Any requiring treatment within 5 years (except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated)
  • Has abnormal thyroid function with clinical significance
  • Recent hospitalization for stroke, myocardial infarction or coronary revascularization within 30 days prior to screening
  • History of and/or obvious clinical signs or symptoms of cirrhosis or other significant liver disease
  • or aspartate aminotransferase >2 x
  • Most recent hospitalization was for non-cardiovascular or non-renal conditions
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Tonlamarsen

    3 doses active drug will be administered by subcutaneous (under the skin) injection (one dose every 4 weeks)

    Drug: Tonlamarsen

  • Placebo comparator
    Placebo

    3 doses of placebo will be administered by subcutaneous (under the skin) injection (one dose every 4 weeks)

    Drug: Placebo

Interventions

  • Tonlamarsen will be administered subcutaneously (under the skin) every 4 weeks during the randomized part of the study

  • DrugPlacebo

    Placebo will be administered subcutaneously (under the skin) every 4 weeks during the randomized part of the study

07

What researchers measure

Primary outcomes

  1. Part A: To assess variability in clinical and biomarker measures to inform Part B sample-size estimation and study-design assumptions

    * Change from baseline in plasma angiotensinogen (AGT) levels and systolic blood pressure * Variability in plasma AGT levels and systolic blood pressure

    Time frame: Baseline through Week 12

  2. Part B: To assess the pharmacodynamic (PD) effect of tonlamarsen on plasma AGT levels

    Percent change in plasma AGT levels from Baseline to Week 4

    Time frame: Week 4

Secondary outcomes

  1. Part A: To assess the safety and tolerability of tonlamarsen compared with placebo

    * Incidence and severity of treatment emergent adverse events (TEAEs), including serious adverse events (SAEs) and adverse events of special interest (AESIs) * Incidence of clinically significant abnormalities in laboratory assessments, physical examinations, 12-lead electrocardiograms, and vital signs

    Time frame: Week 36

  2. Part A: To assess the feasibility of using AGT levels and systolic blood pressure as efficacy endpoints

    * Change from baseline in plasma AGT levels and systolic blood pressure * Variability in plasma AGT levels and systolic blood pressure

    Time frame: Baseline through Week 12

  3. Part B: To assess the safety and tolerability of tonlamarsen compared with placebo

    * Incidence and severity of treatment emergent adverse events (TEAEs), including serious adverse events (SAEs) and adverse events of special interest (AESIs) * Incidence of clinically significant abnormalities in laboratory assessments, physical examinations, 12-lead electrocardiograms, and vital signs

    Time frame: Week 36

  4. Part B: To evaluate the effect of tonlamarsen on systolic blood pressure measured via daily home blood pressure monitoring

    Change in time-averaged systolic blood pressure measured via daily home blood pressure monitoring from Baseline during Week 4

    Time frame: Week 4

  5. Part B: To evaluate the effect of tonlamarsen on office systolic blood pressure

    Change in office systolic blood pressure from Baseline to Week 4

    Time frame: Week 4

  6. Part B: To assess the PD effect of tonlamarsen on plasma AGT levels

    Percent change in plasma AGT levels from Baseline to Week 12

    Time frame: Week 12

  7. Part B: To evaluate the effect of tonlamarsen on systolic blood pressure measured via daily home blood pressure monitoring

    Change in time-averaged systolic blood pressure measured daily via home blood pressure monitoring from Baseline during Week 12

    Time frame: Week 12

  8. Part B: To evaluate the effect of tonlamarsen on office systolic blood pressure

    Change in office systolic blood pressure from Baseline to Week 12

    Time frame: Week 12

08

Study locations

12 of 13 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2026
First posted
Apr 6, 2026
StartActual
Jun 23, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Feb 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added. 2 sites changed recruiting status (1 now active, not recruiting, 1 now recruiting)
Show 2 sites
  • Richmond University Medical Center (RUMC) · Staten Island, United StatesRecruiting→Active, not recruiting
  • Cleveland Clinic · Cleveland, United StatesNot yet recruiting→Recruiting
Show 2 added (2 United States)
  • Henry Ford Hospital · Detroit, United States
  • Cleveland Clinic · Cleveland, United States
across 3 updates, Sep 29, 2026 – Oct 15, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Richmond University Medical Center (RUMC) · Staten Island, United StatesContact removed c•••@kardigan.bio · •••5135
Sep 30, 2026
Show all 3 updates
  1. Oct 15, 2026
    Cleveland Clinic is now Recruiting
    + 1 other change: verification date
  2. Sep 30, 2026
    Richmond University Medical Center (RUMC) is now Active, not recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Richmond University Medical Center (RUMC) · Staten Island, United StatesContact removed c•••@kardigan.bio · •••5135
  3. Sep 29, 2026
    2 sites added
    Show 2 added (2 United States)
    • Henry Ford Hospital · Detroit, United States
    • Cleveland Clinic · Cleveland, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07511361
Lead sponsor
Kardigan, Inc.
Responsible party
Sponsor
First posted
Apr 6, 2026
Start date
Jun 23, 2026
Primary completion
Dec 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Kardigan Clinical Study Information Team
Contact
clinicaltrials@kardigan.bio
+1-877-310-5135

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tonlamarsen

Start the discussion